Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Intra-articular Lidocaine · 1 trial · 2 indications
Measured via surface EMG decomposition
Measured via surface EMG decomposition
| Arm | Type | Description |
|---|---|---|
| Effusion Group | EXPERIMENTAL | 60 mL sterile saline injected into knee |
| Deafferentation Group | ACTIVE_COMPARATOR | Lidocaine (single intra-articular dose) |
| Control Group | SHAM_COMPARATOR | Sham procedure with fake needle |
| Name | Type | Description |
|---|---|---|
| Joint Effusion via 60 mL Sterile Saline | DEVICE | Injection of sterile saline into the knee joint to simulate joint swelling and induce quadriceps inhibition. |
| Intra-articular Lidocaine | DRUG | Injection of 7 mL lidocaine into the knee joint to simulate deafferentation by temporarily blocking sensory input. |
| Sham injection | OTHER | Simulated knee injection using a stage needle without skin penetration, used to blind participants and serve as control. |
Inclusion Criteria: 1. Age 18-30 years 2. Physically active (Tegner ≥ 5) 3. No prior lower-limb surgery or major injury Exclusion Criteria: 1. Lower limb surgery or significant injury in past 2 years 2. Cardiopulmonary, neurological, or psychiatric disorders 3. Needle/electrical stimulation anxie...
Intra-articular Lidocaine is being studied for muscle inhibition, specifically in the context of simulated knee injury. It is an investigational small molecule in Phase 1 clinical development. The drug is being evaluated for its effects on quadriceps motor unit adaptation following knee injury simulation.
Intra-articular Lidocaine is being developed by Community Health Systems, Inc. (NYSE: CYH). The company is conducting a Phase 1 clinical trial to evaluate the drug for muscle inhibition related to knee injury.
Intra-articular Lidocaine is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing trial is an early Phase 1 study that is currently recruiting participants.
Intra-articular Lidocaine is being studied in a single clinical trial, NCT06999057, titled 'Quadriceps Motor Unit Adaptation to Simulated Knee Injury.' This early Phase 1 study is recruiting 45 participants in the United States and is active but not yet completed.
Intra-articular Lidocaine is a formulation of lidocaine administered into the joint space. While lidocaine is a well-known local anesthetic, this specific intra-articular formulation is being investigated for a new purpose: treating muscle inhibition after knee injury. It is in early clinical development for this indication.